Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

References

• Richardson RG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. myeloma. Blood. 2002;100:3063–3067.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–917.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–1769.
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–216.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–44.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–4530.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
   Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International myeloma working group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10:155–167.
   PubMed Web of Science ®Google Scholar
• Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605–1613.
   PubMed Web of Science ®Google Scholar
• Reece D, Kouroukis CT, Leblanc R, et al. Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus. Adv Hematol. 2012;2012:621958.
   PubMedGoogle Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953–1959.
   PubMed Web of Science ®Google Scholar
• Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164–170.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Görgün G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012;4:253–268.
   PubMedGoogle Scholar
• Dimopoulos MA, Terpos E, Niesvizky R. How lenalidomide is changing the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013;88:S23–S35.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71:625–649.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Dimopoulos M, Weber D. Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis) [abstract]. Blood. 2007;110:2712.
   Web of Science ®Google Scholar
• Chen C, Baldassarre F, Kanjeekal S, et al. Lenalidomide in multiple myeloma-a practice guideline. Curr Oncol. 2013;20:e136–e149.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116:3807–3814.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423–429.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28:4976–4984.
   PubMed Web of Science ®Google Scholar